Why Shares of Invivyd Jumped This Week
Invivyd (NASDAQ:IVVD) Given New $2.00 Price Target at Morgan Stanley
Invivyd (NASDAQ:IVVD – Get Rating) had its target price decreased by Morgan Stanley from $3.00 to $2.00 in a research note published on Tuesday, Benzinga reports. Morgan Stanley currently has an unde
Morgan Stanley Trims Invivyd Price Target to $2 From $3, Maintains Underweight Rating
11:34 AM EST, 01/24/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Morgan Stanley Keeps Their Sell Rating on Invivyd (IVVD)
Morgan Stanley Trims Invivyd (NASDAQ:IVVD) Target Price to $2.00
Invivyd (NASDAQ:IVVD – Get Rating) had its price objective lowered by analysts at Morgan Stanley from $3.00 to $2.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently
Invivyd Price Target Cut to $2.00/Share From $3.00 by Morgan Stanley
Invivyd Price Target Cut to $2.00/Share From $3.00 by Morgan Stanley
Invivyd Is Maintained at Underweight by Morgan Stanley
Morgan Stanley Maintains Underweight on Invivyd, Lowers Price Target to $2
Morgan Stanley analyst Matthew Harrison maintains Invivyd (NASDAQ:IVVD) with a Underweight and lowers the price target from $3 to $2.
Invivyd Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/24/2023 -1.96% Morgan Stanley $3 → $2 Maintains Underweight 09/14/2022 47.06% Morgan Stanley → $3 Maint
12 Health Care Stocks Moving In Monday's After-Market Session
GainersAxcella Health (NASDAQ:AXLA) shares moved upwards by 49.9% to $0.65 during Monday's after-market session. Today's trading volume for this security ended up closing at 1.2 million shares, which
Loading...
No Stock Yet